The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

N/AEnrolling By InvitationNCT06851403

Guangzhou Institute of Respiratory Disease213 enrolled

Overview

Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.

Study Type

OBSERVATIONAL

Enrollment

213

Conditions

Asthma in Children

Interventions

DupilumabDRUG

initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks

Eligibility

Sex: ALLMin age: 4 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period. Exclusion Criteria: Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.

Locations (1)

Guangzhou institute of respiratory disease

Guangzhou, Guangdong, China